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Motor development underlies many aspects of education and learning. There has been uncertainty about the
impact of exposure of antidepressant medication in pregnancy on child motor outcomes. This paper examines
whether exposure to antidepressants in utero increases the risk of poorer motor development in two areas:
sensorimotor and visuospatial processing. Data were obtained from 195 women and children across 3 groups:
women with untreated depression in pregnancy, women treated with antidepressants and control women. Data
were collected across pregnancy, postpartum and until 4 years for mother and child. Maternal depression was
established at baseline with the Structured Clinical Interview for DSM-IV. Antidepressant exposure, including
type, dose and timing, was measured through repeated self-report across pregnancy and the postpartum, medical
records at delivery and in cord blood samples collected at delivery. Child sensorimotor and visuospatial outcomes
were assessed at 4 years of age with four subtests from the NEPSY-II. Our study found for sensorimotor devel
opment, visuomotor precision completion time was associated with better performance for antidepressantexposed children compared to those with mothers with untreated depression. Yet another measure of sensori
motor development, motor manual sequences, was poorer in those exposed to antidepressants. One subtest for
visuospatial processing, block construction, was associated with poorer performance in antidepressant-exposed
children who had poor neonatal adaptation and those exposed to a higher dose of antidepressant. These find
ings suggest an inconsistent association between sensorimotor development and antidepressant use in pregnancy.
However, the findings for visuospatial processing would support further exploration of antidepressant associated
poor neonatal adaption and later motor development.

1. Background
The serotonin system has a role in regulating both muscle tone and
motor output, and this has led to a concern that the developing motor
system may be vulnerable to exposure to serotonergic antidepressants
such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and
noradrenalin reuptake inhibitors (SNRIs) (Galbally et al., 2012). In
addition, alteration in serotonin levels for the fetus may also have wider
neurodevelopmental effects, including for motor development, through
serotonin acting as a molecular signal for neuronal growth and

differentiation.
There have been animal studies, which have shown that SSRI
exposure in pregnancy may specifically impact motor development
(Bairy et al., 2007; Lee, 2009; Zusso et al., 2008). For example, in a study
in postnatal rats, fluoxetine exposure altered cerebellar development
through the activation of serotonin 5-HT1A receptors (Zusso et al.,
2008). In another study, rats exposed to fluoxetine had a delay in motor
development (Bairy et al., 2007), and a third study found reduced lo
comotor activity in the context of an altered structure of the somato
sensory cortex (Lee, 2009). These animal studies have led to human
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studies investigating the relationship between pregnancy exposure to
antidepressants and children’s motor development.
A recent systematic review and meta-analysis specifically examined
associations between antidepressant exposure in pregnancy and child
motor development outcomes (Grove et al., 2018). In total, 18 studies
were included in the meta-analysis. The overall results of this
meta-analysis found a small pooled effect size of 0.22 (95% confidence
interval [CI] = 0.07 to 0.37) for antidepressant exposure on subsequent
poorer motor development. However, subgroup analysis showed dif
ferences in effect size due to measurement type, specifically parent or
clinician report on brief screening measures (7 studies) compared to
standardized neuropsychological measures of motor development, such
as the Bayley’s Scales of Infant Development (11 studies) were more
varied and the pooled effect was lower (d = 0.10, 95% CI -0.05 to 0.24)
(Grove et al., 2018).
A general feature of many studies of developmental outcomes for
children exposed in utero to antidepressants has been the limited length
of follow up for child developmental outcomes. The consequence of such
limited follow up in the case of child motor development is the limited
investigation of related aspects of cognitive neurodevelopment. Infant
motor development is an important precursor of later cognitive neuro
development, particularly sensorimotor and visuospatial abilities in
early childhood (Davis et al., 2011; Wilson et al., 2013). Given the
increasing emphasis on cognition as embodied, it is necessary to test
developmental outcomes within a dynamic model in which brain, body
and environment interact over time (Smith, 2005).
In 2020, Fitton and colleagues published a systematic review
examining studies on antidepressant exposure in utero on a range of
infant and child outcomes (Fitton et al., 2020). This important review
addressed a common criticism of previous studies, the authors restricted
their review to studies that compared controls to not only a group where
the fetus had been exposed to SSRIs, but also an untreated depressed
group (to account for confounding by indication with maternal
depression) (Fitton et al., 2020). This review identified only 6 studies
that examined longer-term child outcomes, including only two pro
spective studies. None of the identified studies included examination of
motor or cognitive development.
Given the need for a more robust model of development and the
uncertainty of current findings on the relationship between cognitivemotor development and antidepressant exposure (Grove et al., 2018),
we selected specific aspects of both cognitive and motor development
using subtests measuring specifically sensorimotor and visuospatial
development within a neuropsychological measure, the NEPSY-II (A
Developmental NEuroPSYchological Assessment, 2nd Edition). We
included a study design with three groups: children exposed to antide
pressants in pregnancy, those with mothers with depression in preg
nancy who did not take antidepressants and those with mothers who
were healthy in pregnancy. Furthermore, in addition to self-reported
antidepressant use and dose over pregnancy, we also examined the
relationship to cord blood concentration of antidepressants and the
specific neuropsychological subtests.

Committee approved this study and all participants provided informed,
written consent.
2.1. Measures
2.1.1. Maternal mental health
At recruitment, the Structured Clinical Interview for DSM-IV (SCIDIV) Mood disorders schedule was undertaken by trained administrators
(First et al., 1997).
2.1.2. Antidepressant use
Antidepressant type, dosage and timing during pregnancy was selfreported by women in early pregnancy and again in third trimester, as
well as verified against hospital records at delivery (Galbally et al.,
2017a). As the majority of participants were on sertraline, all doses of
antidepressants were converted to a sertraline-equivalent dosage (SED)
using a conversion chart (Procyshyn et al., 2015). The average dose
across pregnancy was used in the analyses. As previously described, cord
blood was collected at delivery, centrifuged and plasma stored at − 80 ◦ C
(Galbally et al., 2017a). The SSRIs citalopram, escitalopram, fluoxetine,
norfluoxetine, paroxetine and sertraline were analyzed with liquid
chromatography–mass spectrometry (LC–MS) and the SNRIs duloxetine,
venlafaxine and desvenlafaxine were analyzed with ultra-high perfor
mance
liquid
chromatography–tandem
mass
spectrometry
(UHPLC–MS–MS) (Galbally et al., 2017a). In order to compare con
centrations across the various antidepressants, a drug level measured
within a sample was standardized by relating it to the middle of the
therapeutic reference range of that drug (Hiemke and Hartter, 2000).
Thus, the degree of fetal exposure could be estimated regardless of the
specific antidepressant taken in pregnancy by the mother.
2.1.3. Neonatal adaptation
Poor neonatal adaptation (PNAS) was measured only in
antidepressant-exposed neonates using the Neonatal Abstinence Scoring
System (NASS). The NASS measure, developed by Finnegan for opiate
withdrawal in neonates, was undertaken twice daily from birth for up to
6 days. At 24 h post-birth, a pediatrician administered the NASS at the
same time as the midwife, however, they were blinded to each other’s
scores. The further details for this sample are presented in a previous
publication (Galbally et al., 2017a). Other relevant variables including
other pregnancy exposures (pharmaceutical, drug, alcohol and smok
ing), pregnancy and neonatal complications, mode of delivery, gesta
tional age at birth, birth weight and Apgar scores were all also collected
(Galbally et al., 2017a, 2017b).
2.1.4. Child motor development
NEPSY-II is a clinician-administered neuropsychological test vali
dated for 3–16 years old (Brooks et al., 2009). For this study, we utilised
those subtests thought to have the strongest relationship to motor
development, including sensorimotor and visuospatial processing. These
subtests under the sensorimotor domain were i) Manual Motor
Sequence, ii) Visuomotor Precision (Combined, Total Errors and
Completion Time). Manual motor sequence involves the child repli
cating demonstrated movement sequences with each and both hands.
Visuomotor precision assesses graphomotor speed and accuracy through
the speed and accuracy of a child being able to draw lines inside a track.
For visuospatial processing the subtests were iii) Design Copying and iv)
Block Construction. Design copying involves the child copying a two
dimensional figure. Block construction requires a child to reproduce a
three dimensional block model from each another model or a two
dimensional drawing of a model. All of these subtests are associated with
assessment of motor delays and disorders (Brooks et al., 2009). In this
study, we utilise scaled scores, where higher scores reflect better and/or
faster performance on subtests. The trained psychologists who admin
istered the NEPSY were blind to the group status of participants.

2. Methods
This study draws on participants from the Mercy Pregnancy
Emotional Wellbeing Study, a prospective, selected cohort pregnancy
study where women recruited before 20 weeks of pregnancy and their
children followed are up until 4 years postpartum. This study utilizes
data from 195 women and their children who have complete data on the
study variables from pregnancy until 4 years of age. Study participants
comprised three groups: those with maternal depression at recruitment
verified with a diagnostic measure, but not on antidepressant medica
tion (Untreated, Currently Depressed; n = 21), those on antidepressant
medication (AD Exposed; n = 33) and control women (Control; n = 141).
Further details of the study are described in the published study protocol
(Galbally et al., 2017b). The Mercy Health Human Research Ethics
2
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2.1.5. Maternal cognition
To assess maternal cognition, the Test of Premorbid Functioning
(TOPF) was undertaken. This is a validated screening test for cognitive
ability in adults, and consists of a test of 70 atypical words (Wechsler,
2011).

Table 1
Sociodemographic and Other Key Variable Descriptive Statistics for the MPEWS
Sample who Completed the NEPSY-II at 4 Years of Age, by Group (N = 195).

2.2. Statistical analyses
For NEPSY-II subtests with only percentile ranks, we converted the
raw scores to comparable scaled scores (Mean = 10, Standard Deviation
= 3) by first converting raw scores to z-scores, then multiplying by 3 and
adding 10. In analyses using the above scaled score conversion (i.e.,
Manual Motor Sequence, Design Copying and Visuomotor Precision
Total Errors), we control for child’s age at the time of neurocognitive
testing (Rosenqvist et al., 2016). We first conducted a MANCOVA to test
for differences in NEPSY-II subtests between the three groups (Un
treated, Currently Depressed, AD Exposed, Control). In the MANCOVA
model, we also adjusted for the effects of maternal cognitive Test of
Premorbid Function (TOPF) scores and the child’s gestational age at
birth. To assess for dose effects, we conducted ANCOVA models using a
subsample of only the children in the AD Exposed group to examine the
effect of higher reported SED (daily dose ≥ 100 mg/d SED) compared to
lower SED (daily dose < 100 mg/d SED) on NEPSY-II subtests. In these
ANCOVA models, we adjusted for maternal TOPF scores and child’s
gestational age.
We then estimated bivariate associations (Spearman’s rho) between
antidepressant concentration detected in cord plasma and NEPSY-II
subtests. Due to a zero-inflated, non-normal distribution of relative
cord plasma antidepressant concentrations, a constant was added (i.e. x
+ 1) and the variable was transformed using the natural logarithm,
which improved the non-zero part of the distribution. Finally, using
NASS latent intercept factor scores from an intercept-only model of
change in NASS scores (separate models for CNS, gastrointestinal, and
other symptoms, as well as total symptom scores, more details are
published (Galbally et al., 2017a) measured at days 1, 2, 3 and 4
following delivery, we estimated bivariate Spearman’s rho correlations
between these NASS factor scores and cord plasma antidepressant con
centrations and between NASS factor scores and performance on the
NEPSY-II subtests.
Power analysis were conducted to determine how small an effect
(partial η2) the sample (n = 195) is powered to detect, using an alpha
level of 0.05 and power level of 0.80. For the MANCOVA models
adjusted for 3 covariates and including 6 outcome variables, the 195
sample is powered to detect an effect for the multivariate main effect for
group (i.e., untreated currently depressed, AD exposed, and control) as
small as partial η2 < 0.02. For the univariate models, the 195 sample is
powered to detect an effect for the main effect for group as small as
partial η2 = 0.06. For tests using subsets of the full sample, statistical
power is limited; however, we report these findings as exploratory and
include observed effect sizes, which will contribute to future metaanalyses on this topic.

Caucasian
Nulliparous
Tertiary education
Full-time employment
Married, de facto, or
otherwise stable
relationship
SGA
Apgar < 7 at 5 min
Male
MOD
SVD
Assisted VD
CS

Maternal age at
recruitment (y)
Maternal Test of
Premorbid
Functioning
Gestation at birth
(weeks)
Birthweight (kg)
Scaled NEPSY-II Subtests
Block Construction
Design Copying^
Manual Motor
Sequences^
Visuomotor
Precision Total
Errors^
Visuomotor
Precision
Completion Time
Visuomotor
Precision Combined

pvalue

Control
(n = 141)

Untreated,
Currently
Depressed (n =
21)

AD
Exposed (n
= 33)

n (Valid
%)

n (Valid %)

n (Valid %)

125
(89.3)
136
(96.5)
99 (70.7)
101
(73.2)
135a
(96.4)

19 (90.5)

30 (90.9)

.955

21 (100.0)

31 (93.9)

.505

14 (66.7)
11 (57.9)

16 (48.5)
17 (54.8)

.052
.079

21a (100.0)

27b (81.8)

.002

14 (9.9)
4 (2.8)
79 (56.0)

1 (4.8)
1 (4.8)
14 (66.7)

2 (6.1)
2 (6.3)
15 (45.5)

62 (44.0)
30 (21.3)
49 (34.8)

6 (28.6)
5 (23.8)
10 (47.6)

15 (45.5)
7 (21.2)
11 (33.3)

.617
.618
.298
.723

M (SD)

M (SD)

M (SD)

31.72
(4.39)
55.22
(11.53)

30.86 (4.77)

33.00
(5.11)
54.58
(9.18)

39.50
(1.71)
3.41 (.50)

39.41 (1.88)

11.39
(3.33)
10.07
(2.15)
10.21a
(2.99)
9.85
(2.77)

11.35 (1.93)

54.80 (7.68)

3.46 (.59)

10.04 (3.05)
10.57a,b (3.46)
9.78 (3.34)

pvalue
.203
.498

38.71
(1.38)
3.31 (.49)

.053

10.33
(3.61)
9.77 (3.30)

.245

8.77b
(2.42)
10.78
(3.62)

.021^^

.514

.895

.260

10.98a
(2.44)

9.71a (2.17)

11.82b
(2.28)

.008

8.85
(2.72)

8.10 (3.03)

9.00 (2.98)

.466

Note. Cells with different sub-script letters have significantly different group
parameters at p < .05 using pairwise comparison tests. MOD, mode of delivery;
SVD, spontaneous vaginal delivery; VD, vaginal delivery; CS, caesarean section;
PR, percentile rank; y, years; kg, kilogram; SGA, small for gestational age; M,
Mean; SD, Standard Deviation; AD, antidepressant.^ Scaled score = z raw NEPSY
sub-test score*3 + 10.^^ Robust Welch F Test due to unequal variances; pairwise
comparisons conducted using Dunnett C post-hoc tests. Missing data handled
using casewise exclusion, with valid percentages presented.

3. Results

3.2. NEPSY-II performance by group

3.1. Sample characteristics

Table 1 displays scaled means for the NEPSY-II subtest and accom
panying significance of unadjusted F tests. There were no differences in
the scaled means for Block Construction, Design Copying and the
Visuomotor Total Errors and Combined subtests. However, there were
significant group differences for the Manual Motor Sequence and
Visuomotor Precision Completion Time subtests. For the Manual Motor
Sequence subtest, pairwise comparisons demonstrated that children
whose mothers were taking antidepressants during pregnancy scored
significantly lower than children whose mothers were in the control
group. Conversely, pairwise comparisons demonstrated that children
whose mothers were depressed during pregnancy but did not use

Table 1 displays sociodemographic characteristics of the sample who
completed the NEPSY-II at 4 years old. Table 2 presents summary sta
tistics for antidepressant use during pregnancy. Sertraline was the most
prescribed antidepressant. Two women commenced taking antidepres
sant in third trimester, and one woman who was taking antidepressants
in early pregnancy had ceased by third trimester. Seven women reported
a lower dose and one woman reported a higher dose in third trimester
compared to early pregnancy. Two women changed agents from early
pregnancy to third trimester: paroxetine to fluoxetine and citalopram to
sertraline, respectively.
3
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Table 2
Summary Descriptive Statistics for the 33 Patients Using Antidepressants During Pregnancy in this MPEWS Sample.
Antidepressant Class and name

Early Pregnancy

Third Trimester

(n = 32)
n
SSRI
Fluoxetine
Sertraline
Escitalopram
Citalopram
Paroxetine
SNRI
Venlafaxine
Desvenlafaxine
Duloxetine
Other
Mirtazapine

(n = 31)
%

Sertraline-equivalent Dose (mg/d)
Median

Min - Max

n

%

Sertraline-equivalent Dose (mg/d)
Median

Min - Max

3
8
5
4
2

9.4
25
15.6
12.5
6.3

100
75
87.5
37.5
34.4

–
50.0–200.0
50.0–100.0
25.0–50.0
18.8–50.0

4
10
5
3
1

12.9
32.3
16.1
9.7
3.2

50
75
100
50
50

12.5–100.0
50.0–150.0
50.0–400.0
25.0–50.0
–

4
3
2

12.5
9.4
6.3

56.3
37.5
100

37.5–75.0
25.0–50.0
–

2
3
2

6.5
9.7
6.5

65.6
25
100

56.3–75.0
–
–

1

3.1

16.7

–

1

2.3

–

–

Note. SSRI, Selective Serotonin Reuptake Inhibitor; SNRI, Serotonin and Noradrenaline Reuptake Inhibitor. Min-Max is not given (− ) if the dose was the same in all
subjects or if n = 1.

antidepressants scored significantly lower on the Visuomotor Precision
Completion Time subtest than children whose mothers were taking
antidepressants during pregnancy.
Fig. 1 displays the estimated marginal means adjusted for covariates
at the sample means for the MANCOVA model using the linear multi
variate combination of the six NEPSY-II subtests. None of the covariates
were significant in the multivariate model (maternal TOPF, F[6, 154] =
1.34, p = .243, partial η2 < 0.05; gestational age at birth, F[6, 154] =
1.68, p = .130, partial η2 = 0.06; and child’s age at neurocognitive
assessment, F[6, 154] = 1.63, p = .233, partial η2 = 0.05). The effect of
group in the multivariate model was significant, F(12, 310) = 2.13, p =
.015, partial η2 = 0.08. Univariate F-tests showed a significant effect of
group for Visuomotor Precision Completion Time only, F(2, 165) = 5.59,
p = .004, partial η2 = 0.06; pairwise comparison tests demonstrated that
the AD Exposed group scored significantly higher than the Untreated,
Currently Depressed group (p = .003).

means for the SED groups. There were no significant differences between
SED groups on the Design Copying (F[1, 23] = 0.44, p = .515, partial η2
= 0.02), Manual Motor Sequences (F[1, 23] = 1.62, p = .218, partial η2
= 0.07), Visuomotor Precision Total Errors (F[1, 23] = 2.25, p = .147,
partial η2 = 0.08), and Visuomotor Precision Combined (F(1, 24) = 0.16,
p = .693, partial η2 < 0.01) subtests. However, significantly higher
Visuomotor Precision Completion Time scores were observed among
children in the higher SED compared to the lower SED group, F(1, 24) =
4.62, p = .042, partial η2 = 0.16. Conversely, significantly lower Block
Construction scores were observed for children in the higher SED group
compared to the lower SED group, F(1, 24) = 7.57, p = .011, partial η2 =
0.24.
Fig. 3 illustrates the bivariate associations between relative cord
plasma antidepressant concentration and scaled NEPSY-II subtest scores.
Only the positive correlation between cord plasma antidepressant con
centration and performance on the Visuomotor Precision Completion
Time subtest was significant (rho[28] = 0.42, p = .028; see Fig. 3[e]), i.
e., higher antidepressant cord drug concentrations were associated with
shorter completion time on the Visuomotor Precision subtest. Although
not significant at p < .05, there was a trending negative correlation
between cord plasma antidepressant concentration and performance on
the Manual Motor Sequences subtest (rho[28] = -.38, p = .054; see Fig. 3
[c]), i.e. higher antidepressant cord drug concentrations may be asso
ciated with poorer performance.

3.3. Associations between antidepressant dose/concentration and
NEPSY-II performance
Using only children exposed to antidepressants during pregnancy, a
series of univariate ANCOVA models were run comparing SED groups
(daily dose < 100 mg/d SED and daily dose ≥ 100 mg/d SED) on the
child’s NEPSY-II performance. Fig. 2 displays the estimated marginal

Fig. 1. Univariate Estimated Marginal
Means (and standard errors as error bars) for
MPEWS groups for the selected scaled
NEPSY-II subtests as outcomes. Estimates are
adjusted for maternal TOPF scores, gesta
tional age at birth and child’s age at time of
NEPSY-II assessment. BC, Block Design; DC,
Design Copying; MMS, Manual Motor Se
quences; VP, Visuomotor Processing; AD,
antidepressant. ^ Scaled score = zraw NEPSY
sub-test score*3 + 10. * Denotes significant
pairwise comparison test (p < .05) with
Bonferroni adjustment for multiple pairwise
comparisons within univariate tests.
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Fig. 2. Univariate estimated marginal
means (and standard errors as error bars)
across SED groups for the selected scaled
NEPSY-II subtests as outcomes in children
exposed to antidepressants in utero. Esti
mates are adjusted for maternal TOPF scores
and gestational age at birth^. BC, Block
Design; DC, Design Copying; MMS, Manual
Motor Sequences; VP, Visuomotor Process
ing; SED, sertraline-equivalent dose. ^ Scaled
score = zraw NEPSY sub-test score*3 + 10. Child’s
age at time of neurocognitive testing also
included in models as covariate.

Fig. 3. Scatterplots displaying the bivariate associations between the antidepressant concentration in cord plasma and the selected scaled NEPSY-II Subtest scores.

3.4. Associations between NASS and antidepressant concentrations and
NEPSY-II performance

antidepressant concentrations with the NASS using MPEWS data is
published (Galbally et al., 2017a). Only the NASS total factor score was
associated with the specific subtests on the NEPSY-II. Specifically, there
was a marginally negative association between NASS total factor score
and the Block Construction scaled subtest (rho[28] = -.36, p = .052),
suggesting that higher total scores on the NASS during the first 4 days of

There were no significant bivariate associations between cord
plasma antidepressant concentration and any of the NASS factors scores
(p’s > 0.05). A comprehensive analysis between cord plasma
5
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life was associated with lower scaled Block Construction subtest scores.

examining longer term sequalae including motor development following
PNAS associated with antidepressant exposure and this includes re
ported previous findings from this study (Galbally et al., 2015, 2017a;
Klinger et al., 2011). Our findings suggest further research is warranted
examining PNAS and longer-term child development.
Previous research focusing on maternal depression as such has found
an association with poorer motor outcomes in children, including a
recent study that found only an impact for current antenatal depression
on motor development outcomes in children but not a history of
depression without current symptoms (O’Leary et al., 2019). Our find
ings suggest that antenatal depression may influence motor develop
ment and in particular visuomotor development and treatment may be
protective of this, but our findings are not conclusive and require further
research.
Although not significant at 0.05 (p = .052), fewer women in the AD
Exposed group compared to the control and untreated, currently
depressed groups, reported having completed a tertiary education. With
larger numbers, this effect may be significant and should be considered
as a confounding factor between antidepressant exposure in utero and
offspring neurocognitive development in future studies. A strength of
the current study, however, is the inclusion of a measure of maternal
intelligence, using the TOPF, which is considered a stable measure of
intellectual functioning regardless of the presence of illness or impair
ment. Despite including this brief screening measure for maternal
cognition, rather than relying on education to infer functioning, more
comprehensive testing of maternal and paternal cognition would be
preferable.
While the methodological strengths of this study have been
mentioned, the limitations include the relatively low numbers of chil
dren both exposed to antidepressants and with mothers with untreated
depression in pregnancy. Furthermore, while this study utilised a spe
cific neuropsychological measure there are more specific and compre
hensive measures of child motor development such as the Movement
ABC (Ellinoudis et al., 2011). Further testing at an older age would be
also useful to further understand the dynamics of motor development.
We have considered the antidepressants included in this study as a
group. Although they exhibit somewhat different mechanisms of action,
increasing synaptic levels of serotonin is a common feature. Moreover,
in about two thirds of the cases, the drug was an SSRI. Mirtazapine,
which is the drug with the most separate mechanism of action, con
tributes with one case only. Our results could therefore be considered
more valid for the SSRI and SNRI groups than for mirtazapine. Adjusting
doses by using the SED may introduce bias, although methods of
standardising doses of different drugs within the same class are widely
used to be able to study dose/effect relationships and thereby increase
the credibility of the results. It is also a methodological limitation that
the time interval between the last intake of the drug and sampling was –
for obvious reasons – not possible to standardise. Therefore, in an un
known proportion of the cases, when this interval was short, the
measured concentration would be higher than if the sample had been
obtained 12 to 24 hours after intake, for which the therapeutic reference
ranges are related to. However, as there is no reason to believe that it
should be more samples obtained shortly after drug intake in cases with
higher or lower scores in any of the outcomes studied, the misclassifi
cation would be non-differential and therefore only cause bias towards
the null. Therefore, we consider that our statistically significant corre
lations involving plasma concentrations are valid in this perspective, but
it could have happened that some true associations have not been
revealed.
Although our study was unable to provide conclusive outcomes, it
does point to a new path for research in understanding antidepressant
exposure and child developmental outcomes. The findings demonstrate
the importance of a true depressed comparison group – our untreated
depressed sample met current diagnostic criteria for depression,
including careful measurement of exposure to delineate potential bio
logical effects of exposure from potential silent confounders and

4. Discussion
This study found an inconsistent pattern of associations with anti
depressant exposure across the neuropsychological subtests of sensori
motor and visuospatial processing. Within the assessments of
sensorimotor development, the visuomotor precision subtest was asso
ciated with better performance in children exposed to antidepressants
than those exposed to untreated current depression; furthermore, this
higher performance was associated with both higher reported antide
pressant dose and higher cord blood levels. Whereas on another test of
sensorimotor development, manual motor sequences, children whose
mothers reported antidepressant use in pregnancy scored lower than
children in the control group; however, there was no significant asso
ciation between manual motor sequences with antidepressant dose or
cord blood levels. For the subtest assessing visuospatial processing,
block construction, there was no association with reported antidepres
sant use in pregnancy; however, higher symptoms of PNAS and higher
reported antidepressant dose were both associated with poorer perfor
mance on this subtest. There were no other significant differences for
antidepressant exposed children on the other subtests examined. It is
also important to consider the magnitude of effects identified. The
standard deviation for subtest scaled scores is 3 and the observed sta
tistical significance demonstrated relative small differences between
groups as it was within the region of one standard deviation.
This study builds on the recommendations from two recent relevant
reviews for future research and with improved methodology when
examining antidepressant exposure and child motor and neuro
developmental outcomes (Fitton et al., 2020; Grove et al., 2018). These
recommendations included using a three-group design that incorporates
a group that has current depression not treated with antidepressants to
control for the effect of underlying maternal depression. Furthermore,
inclusion of a measure of maternal cognition and other important con
founding factors, and careful characterisation of exposure to antide
pressants were proposed. We included multi-method data collection on
exposure to antidepressants using self-report, verified with hospital re
cords, and cord blood concentrations, and collected timing, type and
dose of antidepressant.
Motor development has been consistently linked to cognitive and
language development (Oudgenoeg-Paz et al., 2015, 2017). As such,
understanding any deleterious impact from antidepressant exposure or
maternal depression on motor development is important, not only to
understand this impact, but also for understanding the potential impli
cations for broader developmental outcomes. However, this also has
implications for measuring motor development with many tests over
lapping in multiple domains of neurodevelopment. Our study chose four
subtests, which examined sensorimotor development and visuospatial
processing. Our findings indicated antidepressant exposure was associ
ated with both poorer and improved performance across these specific
subtests, and also not consistent across antidepressant dose and cord
levels. For a clear neuroteratogenic finding, there is a requirement to
demonstrate not only an association with use but also dose and timing,
as well as a clear explanatory mechanism that underpins the relationship
between exposure on the specific developmental outcome (Cicchetti and
Walker, 2003). Our findings do not support a neuroteratogenic model
but suggest that longer term follow up should continue to examine both
motor and cognitive development, as well as their complex and subtle
interplay.
Another interesting aspect of our findings were those relating to
PNAS, as an association between antidepressant exposure in pregnancy
and PNAS has been a consistent finding in studies, although the mech
anism remains elusive. For instance, there is no current evidence to
support PNAS as either a discontinuation syndrome or due to seroto
nergic toxicity (Grigoriadis et al., 2013). While in the short term it ap
pears these symptoms resolve, there have been three previous studies
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nuanced and specific measures of child developmental outcomes. Ulti
mately, the aim of research examining child outcomes following anti
depressant exposure in pregnancy is to provide women and clinicians
with clarity on risks and benefits of treatment and also inform options in
terms of agent, dose and timing of antidepressant treatment in preg
nancy. It will only be with the expansion of knowledge through research
that is carefully and specifically designed that the question of the impact
of antidepressant medication on child outcomes will be answered.
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